Autres

Creating Drugs at the Speed of Ai Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug CreationTM platform unlocks the potential to accelerate time to clinic and increase the probability of success by … [voir plus]

Designing functional antibodies for the most challenging targets. Antiverse is a Welsh techbio company specialising in antibody design for challenging drug targets, such as GPCRs and ion channels. We exist to create new enabling technologies that bring new therapies to patients to change lives. Headquartered in Cardiff, UK and with … [voir plus]

Rational design of new molecules and medicines, enabled by the fusion of artificial intelligence and structural biology. Atomic AI is a well-funded, early-stage biotech company transforming the rational design of molecules and medicines through the cutting-edge fusion of artificial intelligence and structural biology. Atomic’s unique R&D platform, based on research … [voir plus]

BigHat Biosciences is a novel protein therapeutics company and developer of an AI-guided antibody design platform BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to … [voir plus]

Pioneering generative biology to create breakthrough therapeutics. Pioneering generative biology to create breakthrough therapeutics. [voir plus]

#insilicomeds, #drugdiscovery, #ai, #GANs, #GANs-RL, #DL #aging, #longevity Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning … [voir plus]

Building the future of cell-based therapies. CAR-T is for more than just oncology. Using the full potential of gene editing, we are creating a therapeutic platform for cell based therapies that are not just disease modifying: they are curative and definitive. Cell-based Therapies and Machine Learning [voir plus]

Bridging Vision & Precision Paige is using the power of AI to drive a new era of cancer discovery and treatment. To improve the lives of patients with cancer, Paige has created a cloud-based platform that transforms pathologists’ workflow and increases diagnostic confidence as well as productivity, all on a … [voir plus]

Decoding the language of life with AI Profluent is an AI-first protein design company. Founded in 2022, we develop deep generative models to design and validate novel, functional proteins to revolutionize biomedicine. Based in Berkeley, CA, we are backed by leading investors including Spark Capital, Insight Partners, Air Street Capital, … [voir plus]